Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus

被引:85
作者
Wu, Tianfu [1 ]
Qin, Xiangmei [1 ]
Kurepa, Zoran [1 ]
Kumar, Kirthi Raman [1 ]
Liu, Kui [1 ]
Kanta, Hasna [1 ]
Zhou, Xin J. [1 ]
Satterthwaite, Anne B. [1 ]
Davis, Laurie S. [1 ]
Mohan, Chandra [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Internal Med, Div Rheumatol, Dallas, TX 75230 USA
关键词
ERYTHEMATOSUS SUSCEPTIBILITY LOCUS; NEW-ZEALAND BLACK; SYSTEMIC-LUPUS; AUTOIMMUNE-DISEASE; PHASE-II; T-CELL; PHOSPHATIDYLINOSITOL; 3-KINASE; TEMSIROLIMUS CCI-779; MAMMALIAN TARGET; SLE PATHOGENESIS;
D O I
10.1172/JCI30398
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Though B cells play key roles in lupus pathogenesis, the molecular circuitry and its dysregulation in these cells as disease evolves remain poorly understood. To address this, a comprehensive scan of multiple signaling axes using multiplexed Western blotting was undertaken in several different murine lupus strains. PI3K/AKT/ mTOR (mTOR, mammalian target of rapamycin), MEK1/Erk1/2, p38, NF-kappa B, multiple Bcl-2 family members, and cell-cycle molecules were observed to be hyperexpressed in lupus B cells in an age-dependent and lupus susceptibility gene-dose-dependent manner. Therapeutic targeting of the AKT/mTOR axis using a rapamycin (sirolimus) derivative ameliorated the serological, cellular, and pathological phenotypes associated with lupus. Surprisingly, the targeting of this axis was associated with the crippling of several other signaling axes. These studies reveal that lupus pathogenesis is contingent upon the activation of an elaborate network of signaling cascades that is shared among genetically distinct mouse models and raise hope that targeting pivotal nodes in these networks may offer therapeutic benefit.
引用
收藏
页码:2186 / 2196
页数:11
相关论文
共 65 条
[1]   Influence of immunosuppressive drugs on dendritic cells [J].
Abe, M ;
Thomson, AW .
TRANSPLANT IMMUNOLOGY, 2003, 11 (3-4) :357-365
[2]   Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function [J].
Anzelon, AN ;
Wu, H ;
Rickert, RC .
NATURE IMMUNOLOGY, 2003, 4 (03) :287-294
[3]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[4]   Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion [J].
Barber, DF ;
Bartolomé, A ;
Hernandez, C ;
Flores, JM ;
Fernandez-Arias, C ;
Rodríguez-Borlado, L ;
Hirsch, E ;
Wymann, M ;
Balomenos, D ;
Carrera, AC .
JOURNAL OF IMMUNOLOGY, 2006, 176 (01) :589-593
[5]  
Borlado LR, 2000, FASEB J, V14, P895
[6]   Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [J].
Chan, S ;
Scheulen, ME ;
Johnston, S ;
Mross, K ;
Cardoso, F ;
Dittrich, C ;
Eiermann, W ;
Hess, D ;
Morant, R ;
Semiglazov, V ;
Borner, M ;
Salzberg, M ;
Ostapenko, V ;
Illiger, HJ ;
Behringer, D ;
Bardy-Bouxin, N ;
Boni, J ;
Kong, S ;
Cincotta, M ;
Moore, L .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5314-5322
[7]   LPR AND GLD - SINGLE GENE MODELS OF SYSTEMIC AUTOIMMUNITY AND LYMPHOPROLIFERATIVE DISEASE [J].
COHEN, PL ;
EISENBERG, RA .
ANNUAL REVIEW OF IMMUNOLOGY, 1991, 9 :243-269
[8]   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery [J].
Datta, SR ;
Dudek, H ;
Tao, X ;
Masters, S ;
Fu, HA ;
Gotoh, Y ;
Greenberg, ME .
CELL, 1997, 91 (02) :231-241
[9]  
DEL PL, 1997, SCIENCE, V278, P687
[10]  
Deng C, 2001, ARTHRITIS RHEUM, V44, P397, DOI 10.1002/1529-0131(200102)44:2<397::AID-ANR59>3.0.CO